Navigation Links
Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow

GAITHERSBURG, Md., May 24, 2007 /PRNewswire-FirstCall/ -- Iomai Corporation today announced that it will announce results from the Phase 1 trial of its patch-based needle-free influenza vaccine before the markets open tomorrow. A conference call and live webcast will be held at 8:30 a.m. Eastern Time tomorrow to discuss the results.

Conference Call Details

To access the live conference call Friday, May 25, 2007 at 8:30 a.m. Eastern Time via phone, please dial 888-396-2356 from the United States and Canada or 617-847-8709 internationally. The conference ID is 63780500. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through June 1, 2007 and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 75528925.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the Company's website at http://www.iomai.com . Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.

CONTACT: Russell P. Wilson, Senior Vice President, Chief Financial Officerand General Counsel, of Iomai Corporation, +1-301-556-4478,; or Brian Reid of WeissComm Partners, Inc.,+1-703-402-3626, , for Iomai Corporation investors@iomai.com breid@weisscommpartners.com

Web site: http://www.iomai.com/

Ticker Symbol: (NASDAQ-NMS:IOMI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017  Palladian Health, a leading provider ... launch of an opioid management program which assists ... and helps stem the growing tide of dependence ... treat chronic non-cancer pain (back pain, neck pain, ... lack of evidence regarding long-term effectiveness. ...
(Date:1/20/2017)... January 20, 2017 Avillion LLP, a co-developer ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr ... USA . ... Dr Weinberg has spent more than 17 years as a ... companies to micro-cap biotech. Over the course of his career, he ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 Report ... Ophthalmic Devices Market? Which areas are going to grow ... potential revenues to 2026, assessing data, trends, opportunities and ... and graphs. Discover the most lucrative areas in the ... lets you assess forecasted sales across the all the ...
Breaking Medicine Technology:
(Date:1/20/2017)... Missoula, MT (PRWEB) , ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA ... use, saving deck space. Since the lift is mounted on wheels, it can be wheeled ... a lock down kit, to fasten to the deck. "We have transformed the feedback from ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body care ... announced the company had a successful visit to the 2017 ECRM Diet, Vitamin & ... that work in the nutritional, sports and health industries a chance to meet in ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company ... with school-aged children since the holiday season. , “It happens every year around ... sharing hugs and taking photos, which is the head-to-head gateway that lice need to ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years ... Betsy, the clinical trial has been life-saving as she has been on the ... Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but ...
(Date:1/20/2017)... ... ... “Mary Magdalene: Grace is Greater than Sin”: a unique and memorable piece ... “Mary Magdalene: Grace is Greater than Sin” is the creation of published author, Brenda ... women who had little knowledge of the female characters portrayed in the Holy Bible. ...
Breaking Medicine News(10 mins):